Ono Pharmaceutical has agreed to buy cancer drugmaker Deciphera Pharmaceuticals in a deal that values the latter company at $2.4 billion. Per deal terms, Ono is purchasing in cash all outstanding ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
Long-established in the Drug Manufacturers industry, Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has enjoyed a stellar reputation. However, it has recently witnessed a daily loss of 2.19%, juxtaposed ...
On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...
Deciphera Pharmaceuticals, Inc. DCPH announced that it has dosed the first patient in a phase I study which is evaluating its investigational ULK kinase inhibitor, DCC-3116, for the treatment of ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
- Data Featured at the ESMO World Congress on Gastrointestinal Cancer 2020 Virtual Meeting - “The data presented today further reinforce the potential of QINLOCK to provide meaningful clinical benefit ...
In less than 24 hours, the FDA handed out one rejection and one thumbs-up to two rival drugs for a rare stomach cancer. On the heels of turning down Blueprint Medicines’ Ayvakit as a therapy for ...
Deciphera Pharmaceuticals recently took a serious hit to its billion-dollar hopeful cancer drug Qinlock. As the company undertakes a round of layoffs to deal with the blow, newly unveiled data offer a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results